Some drug makers pay key leaders in a field of medicine, such as chairs of departments in medical schools, tens of thousands of dollars if they are saying the right things about their product. They manipulate medical education sessions, lectures, articles in medical journals, research studies, even personal conversations between physicians to get their product message across.
Now a huge collection of drug company internal documents—revealed as part of a law-suit-offers a wealth of detail. In 1996, Dr. David Franklin, an employee of the drug company Parke-Davis, filed the lawsuit under federal whistleblower statutes alleging that the company was illegally promoting a drug called Neurontin for so called "off-label" uses. Under federal law, once the FDA approves a drug, a doctor can prescribe it for anything. But the law specifically prohibits the drug company from promoting the drug for any unapproved uses. In 2004, the company, by then a division of Pfizer
A. Pfizer is a branch of the drug company Parke-Davis.
B. Pfizer has failed in its attempt to conceal certain information.
C. Pfizer is a part of the Drug Industry Document Archive.
D. Pfizer has done nothing illegal since it acquired Parke-Davis.
Some drug makers pay key leaders in a
field of medicine, such as chairs of departments in medical schools, tens of
thousands of dollars if they are saying the right things about their product.
They manipulate medical education sessions, lectures, articles in medical
journals, research studies, even personal conversations between physicians to
get their product message across. Now a huge collection of drug company internal documents--revealed as part of a lawsuit—offers a wealth of detail. In 1996, Dr. David Franklin, an employee of the drug company Parke-Davis, filed the lawsuit under federal whistleblower statutes alleging that the company was illegally promoting a drug called Neurontin for so called "off-label’ uses. Under federal law, once the FDA approves a drug, a doctor can prescribe it for anything. But the law specifically pr A. without approval. B. far from a label. C. off-line. D. without a label. 我来回答: 提交
|